Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,712635,apparent plasma elimination half-life,"The apparent plasma elimination half-life was 46 +/- 7 min (S.E.) at 29 degrees C as compared to 21 +/- 2 and 25 +/- 6 min at 34 and 39 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),min,46,4296,DB01337,Pancuronium
,712635,apparent plasma elimination half-life,"The apparent plasma elimination half-life was 46 +/- 7 min (S.E.) at 29 degrees C as compared to 21 +/- 2 and 25 +/- 6 min at 34 and 39 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),min,21,4297,DB01337,Pancuronium
,712635,apparent plasma elimination half-life,"The apparent plasma elimination half-life was 46 +/- 7 min (S.E.) at 29 degrees C as compared to 21 +/- 2 and 25 +/- 6 min at 34 and 39 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),min,25,4298,DB01337,Pancuronium
,712635,Total plasma clearance,"Total plasma clearance was 4.3 +/- 0.4 ml/kg/min at 29 degrees C and 10.7 +/- 0.9 and 10.9 +/- 1.5 ml/kg/min at 34 and 39 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),[ml] / [kg·min],4.3,4299,DB01337,Pancuronium
,712635,Total plasma clearance,"Total plasma clearance was 4.3 +/- 0.4 ml/kg/min at 29 degrees C and 10.7 +/- 0.9 and 10.9 +/- 1.5 ml/kg/min at 34 and 39 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),[ml] / [kg·min],10.7,4300,DB01337,Pancuronium
,712635,Total plasma clearance,"Total plasma clearance was 4.3 +/- 0.4 ml/kg/min at 29 degrees C and 10.7 +/- 0.9 and 10.9 +/- 1.5 ml/kg/min at 34 and 39 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),[ml] / [kg·min],10.9,4301,DB01337,Pancuronium
,712635,ED50,"The ED50 of pancuronium (plasma concentration required for a 50% depression of twitch tension) was 0.035 and 0.073 microgram/ml at 29 and 38 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),[μg] / [ml],0.035,4302,DB01337,Pancuronium
,712635,ED50,"The ED50 of pancuronium (plasma concentration required for a 50% depression of twitch tension) was 0.035 and 0.073 microgram/ml at 29 and 38 degrees C, respectively.",Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712635/),[μg] / [ml],0.073,4303,DB01337,Pancuronium
,8424303,delta CBF/delta PaCO2,The cerebrovascular reactivity to hypocapnia (delta CBF/delta PaCO2) was maintained throughout the experimental period and amounted to (95% confidence interval) 9.1 (7.1-11.1) ml x 100 g-1 x min-1 x kPa-1 within the PaCO2 range 3.3-6.3 kPa.,"Cerebral haemodynamic and electrocortical CO2 reactivity in pigs anaesthetized with fentanyl, nitrous oxide and pancuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424303/),[100·ml] / [g·kpa·min],9.1,11556,DB01337,Pancuronium
,6119998,ED50,The ED50 of neostigmine (dose which produced a 50% antagonism) when antagonizing Org NC 45 and pancuronium was 0.011 mg kg-1 and 0.010 mg kg-1 respectively.,Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119998/),[mg] / [kg],0.011,18027,DB01337,Pancuronium
,6119998,ED50,The ED50 of neostigmine (dose which produced a 50% antagonism) when antagonizing Org NC 45 and pancuronium was 0.011 mg kg-1 and 0.010 mg kg-1 respectively.,Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119998/),[mg] / [kg],0.010,18028,DB01337,Pancuronium
,6107104,distribution half-life,The pharmacokinetics could be described using a two-compartment open model with a distribution half-life of approximately 4 min and an elimination half-life of approximately 31 min.,Pharmacokinetics and pharmacodynamics of Org NC 45 in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107104/),min,4,18299,DB01337,Pancuronium
,6107104,elimination half-life,The pharmacokinetics could be described using a two-compartment open model with a distribution half-life of approximately 4 min and an elimination half-life of approximately 31 min.,Pharmacokinetics and pharmacodynamics of Org NC 45 in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107104/),min,31,18300,DB01337,Pancuronium
,6107104,steady-state plasma concentration,The mean steady-state plasma concentration producing a 50% block of the twitch response was 0.137 microgram ml-1 (range 0.118--0.176 microgram ml-1).,Pharmacokinetics and pharmacodynamics of Org NC 45 in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107104/),[μg] / [ml],0.137,18301,DB01337,Pancuronium
,712636,ED50,"Pancuronium (ED50 = 0.041 mg/kg) was 2 times more potent than 3-OH-pancuronium (ED50 = 0.082 mg/kg), 50 times more potent than 17-OH-pancuronium (ED50 = 2.0 mg/kg) and 54 times more potent than 3,17-OH--pancuronium (ED50 = 2.15 mg/kg).",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),[mg] / [kg],0.041,19433,DB01337,Pancuronium
,712636,ED50,"Pancuronium (ED50 = 0.041 mg/kg) was 2 times more potent than 3-OH-pancuronium (ED50 = 0.082 mg/kg), 50 times more potent than 17-OH-pancuronium (ED50 = 2.0 mg/kg) and 54 times more potent than 3,17-OH--pancuronium (ED50 = 2.15 mg/kg).",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),[mg] / [kg],0.082,19434,DB01337,Pancuronium
,712636,ED50,"Pancuronium (ED50 = 0.041 mg/kg) was 2 times more potent than 3-OH-pancuronium (ED50 = 0.082 mg/kg), 50 times more potent than 17-OH-pancuronium (ED50 = 2.0 mg/kg) and 54 times more potent than 3,17-OH--pancuronium (ED50 = 2.15 mg/kg).",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),[mg] / [kg],2.0,19435,DB01337,Pancuronium
,712636,ED50,"Pancuronium (ED50 = 0.041 mg/kg) was 2 times more potent than 3-OH-pancuronium (ED50 = 0.082 mg/kg), 50 times more potent than 17-OH-pancuronium (ED50 = 2.0 mg/kg) and 54 times more potent than 3,17-OH--pancuronium (ED50 = 2.15 mg/kg).",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),[mg] / [kg],2.15,19436,DB01337,Pancuronium
,712636,elimination half-lifes,"The elimination half-lifes were 110, 68, 73 and 71 min for pancuronium and its 3-OH, 17-OH and 3,17-OH derivatives, respectively.",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),min,110,19437,DB01337,Pancuronium
,712636,elimination half-lifes,"The elimination half-lifes were 110, 68, 73 and 71 min for pancuronium and its 3-OH, 17-OH and 3,17-OH derivatives, respectively.",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),min,68,19438,DB01337,Pancuronium
,712636,elimination half-lifes,"The elimination half-lifes were 110, 68, 73 and 71 min for pancuronium and its 3-OH, 17-OH and 3,17-OH derivatives, respectively.",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),min,73,19439,DB01337,Pancuronium
,712636,elimination half-lifes,"The elimination half-lifes were 110, 68, 73 and 71 min for pancuronium and its 3-OH, 17-OH and 3,17-OH derivatives, respectively.",The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/712636/),min,71,19440,DB01337,Pancuronium
,8061260,clearance,"The set of Scott et al with the lowest clearance (2.4 mL/kg/min) shows the best accuracy (MDAPE: 19.5%) and precision (P10: -40%, P90: 16%).",Predictive accuracy of alfentanil infusion in coronary artery surgery: a prebypass study in middle-aged and elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061260/),[ml] / [kg·min],2.4,24143,DB01337,Pancuronium
,2886080,plasma clearance,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg·min],3.7,36689,DB01337,Pancuronium
,2886080,plasma clearance,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg·min],5.2,36690,DB01337,Pancuronium
,2886080,volume of distribution at steady-state,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg],179,36691,DB01337,Pancuronium
,2886080,volume of distribution at steady-state,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg],244,36692,DB01337,Pancuronium
,2877596,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was greater (P less than 0.05) after vecuronium (320 +/- 181 ml/kg; mean +/- SD) than after pancuronium (203 +/- 36 ml/kg).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg],320,42725,DB01337,Pancuronium
,2877596,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was greater (P less than 0.05) after vecuronium (320 +/- 181 ml/kg; mean +/- SD) than after pancuronium (203 +/- 36 ml/kg).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg],203,42726,DB01337,Pancuronium
,2877596,Plasma clearance,Plasma clearance of vecuronium (2.8 +/- 0.9 ml X min-1 X kg-1) was greater than that of pancuronium (1.7 +/- 0.2 ml X min-1 X kg-1; P less than 0.05).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg·min],2.8,42727,DB01337,Pancuronium
,2877596,Plasma clearance,Plasma clearance of vecuronium (2.8 +/- 0.9 ml X min-1 X kg-1) was greater than that of pancuronium (1.7 +/- 0.2 ml X min-1 X kg-1; P less than 0.05).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg·min],1.7,42728,DB01337,Pancuronium
,3161430,total duration of,"Similarly, the total duration of neuromuscular blockade, measured to recovery to 90% of control ECEMG, was significantly shorter in the phenytoin group (122 +/- 25 min compared with 269 +/- 64 min in the control group, P less than 0.01).",Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161430/),min,122,46564,DB01337,Pancuronium
,3161430,total duration of,"Similarly, the total duration of neuromuscular blockade, measured to recovery to 90% of control ECEMG, was significantly shorter in the phenytoin group (122 +/- 25 min compared with 269 +/- 64 min in the control group, P less than 0.01).",Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161430/),min,269,46565,DB01337,Pancuronium
,6132566,clearance,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),[ml] / [kg·min],5.2,46796,DB01337,Pancuronium
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),min,71,46797,DB01337,Pancuronium
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),[ml] / [kg·min],1.8,46798,DB01337,Pancuronium
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),min,140,46799,DB01337,Pancuronium
,2869721,plasma clearance rate,Vecuronium was removed faster from the plasma than pancuronium; this was reflected in a significantly larger plasma clearance rate for vecuronium (4 ml X min-1 X kg-1 vs 1.1 ml X min-1 X kg-1 for pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[ml] / [kg·min],4,54165,DB01337,Pancuronium
,2869721,plasma clearance rate,Vecuronium was removed faster from the plasma than pancuronium; this was reflected in a significantly larger plasma clearance rate for vecuronium (4 ml X min-1 X kg-1 vs 1.1 ml X min-1 X kg-1 for pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[ml] / [kg·min],1.1,54166,DB01337,Pancuronium
,2869721,effective plasma concentrations at 50% recovery of the twitch height,The effective plasma concentrations at 50% recovery of the twitch height were 0.11 +/- 0.02 (vecuronium) and 0.2 +/- 0.03 microgram/ml (pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[μg] / [ml],0.11,54167,DB01337,Pancuronium
,2869721,effective plasma concentrations at 50% recovery of the twitch height,The effective plasma concentrations at 50% recovery of the twitch height were 0.11 +/- 0.02 (vecuronium) and 0.2 +/- 0.03 microgram/ml (pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[μg] / [ml],0.2,54168,DB01337,Pancuronium
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],902,58068,DB01337,Pancuronium
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],914,58069,DB01337,Pancuronium
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],4.9,58070,DB01337,Pancuronium
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],11.3,58071,DB01337,Pancuronium
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,250,58072,DB01337,Pancuronium
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,562,58073,DB01337,Pancuronium
,789085,half-life of the beta-phase,The half-life of the beta-phase varied between 89.5 and 161.5 min.,Clinical pharmacokinetics of pancuronium bromide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/789085/),min,89.5 and 161.5,65904,DB01337,Pancuronium
,789085,apparent volume of distribution of the central compartment,The apparent volume of distribution of the central compartment ranged from 62.9 to145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min.,Clinical pharmacokinetics of pancuronium bromide. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789085/),[ml] / [kg],62.9 to145.5,65905,DB01337,Pancuronium
,789085,plasma clearance,The apparent volume of distribution of the central compartment ranged from 62.9 to145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min.,Clinical pharmacokinetics of pancuronium bromide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789085/),[ml] / [min],57.6 to 187.3,65906,DB01337,Pancuronium
,789085,plasma level,At the first sign of recovery from neuro-muscular blockade the mean pancuronium plasma level was found to be 0.218 mcg/ml.,Clinical pharmacokinetics of pancuronium bromide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789085/),,0.218,65907,DB01337,Pancuronium
,789085,duration of action,The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.,Clinical pharmacokinetics of pancuronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789085/),min,83.4,65908,DB01337,Pancuronium
,789085,time of onset of,The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.,Clinical pharmacokinetics of pancuronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789085/),min,83.4,65909,DB01337,Pancuronium
,3840338,plasma concentrations,"Thirty minutes after the injection, fentanyl plasma concentrations were between 7.7 and 13.6 ng X ml-1.",Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),[ng] / [ml],7.7 and 13.6,70248,DB01337,Pancuronium
,3840338,Elimination half-life,"Elimination half-life was 6-32 hr (mean +/- SD, 17.7 +/- 9.3).",Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),h,17.7,70249,DB01337,Pancuronium
,3840338,heart rate,There was a gradual increase in heart rate from 159 +/- 12 min-1 at the time of skin incision to 173 +/- 15 min-1 at the time of skin closure (P less than 0.05).,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),1/[min],159,70250,DB01337,Pancuronium
,3840338,heart rate,There was a gradual increase in heart rate from 159 +/- 12 min-1 at the time of skin incision to 173 +/- 15 min-1 at the time of skin closure (P less than 0.05).,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),1/[min],173,70251,DB01337,Pancuronium
,3840338,plasma concentrations,Fentanyl plasma concentrations remained virtually unchanged between 30 min (10.6 +/- 1.9 ng X ml-1) and 120 min (9.6 +/- 1.6 ng X ml-1); whereas at the end of surgery most infants moved and breathed spontaneously.,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),[ng] / [ml],10.6,70252,DB01337,Pancuronium
,3840338,plasma concentrations,Fentanyl plasma concentrations remained virtually unchanged between 30 min (10.6 +/- 1.9 ng X ml-1) and 120 min (9.6 +/- 1.6 ng X ml-1); whereas at the end of surgery most infants moved and breathed spontaneously.,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),[ng] / [ml],9.6,70253,DB01337,Pancuronium
,6108777,potency ratio,"The potency ratio varied between 3.4 : 1 and 7.2 : 1, depending upon the definition chosen.",Fazadinium and pancuronium: a pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108777/),1·:,3.4,81291,DB01337,Pancuronium
,6108777,potency ratio,"The potency ratio varied between 3.4 : 1 and 7.2 : 1, depending upon the definition chosen.",Fazadinium and pancuronium: a pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108777/),1·:,7.2,81292,DB01337,Pancuronium
,6842398,volume of the central compartment,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],412,92560,DB01337,Pancuronium
,6842398,volume of distribution at steady state,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],2517,92561,DB01337,Pancuronium
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,1.1,92562,DB01337,Pancuronium
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,25.4,92563,DB01337,Pancuronium
,6842398,terminal elimination half-life,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,125,92564,DB01337,Pancuronium
,6842398,total clearance,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg·min],21,92565,DB01337,Pancuronium
,6842398,onset time,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,14,92566,DB01337,Pancuronium
,6842398,duration of action,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,219,92567,DB01337,Pancuronium
,2849968,steady-state volume of distribution (Vss),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg],309,100901,DB01337,Pancuronium
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg·min],2.4,100902,DB01337,Pancuronium
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg],199,100903,DB01337,Pancuronium
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg·min],1.5,100904,DB01337,Pancuronium
,2849968,durations of action,"The durations of action (injection to 25% recovery of twitch tension) of pipecuronium and pancuronium were similar: 98.0 (36.1) min and 117.2 (35.8) min, respectively.",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),min,98.0,100905,DB01337,Pancuronium
,2849968,durations of action,"The durations of action (injection to 25% recovery of twitch tension) of pipecuronium and pancuronium were similar: 98.0 (36.1) min and 117.2 (35.8) min, respectively.",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),min,117.2,100906,DB01337,Pancuronium
,9646009,concentration ratio (UV/MV),The umbilical/maternal vein concentration ratio (UV/MV) of nondepolarising neuromuscular relaxants varies from 7 to 26% and clinical doses of these drugs may induce partial residual curarisation in neonates.,Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646009/),%,7 to 26,106950,DB01337,Pancuronium
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],6.7,107246,DB01337,Pancuronium
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],9.5,107247,DB01337,Pancuronium
,7173308,elimination half-life,The elimination half-life was 89 +/- 20 min and the plasma clearance was 1.84 +/- 0.38 ml/min/kg.,Pharmacokinetics of pancuronium in man: a linear system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173308/),min,89,112152,DB01337,Pancuronium
,7173308,plasma clearance,The elimination half-life was 89 +/- 20 min and the plasma clearance was 1.84 +/- 0.38 ml/min/kg.,Pharmacokinetics of pancuronium in man: a linear system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173308/),[ml] / [kg·min],1.84,112153,DB01337,Pancuronium
,2861839,half-lives,"Concentrations decreased bi-exponentially with half-lives of 4.6 and 31 min, respectively.",Disposition of vecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),min,4.6,113260,DB01337,Pancuronium
,2861839,half-lives,"Concentrations decreased bi-exponentially with half-lives of 4.6 and 31 min, respectively.",Disposition of vecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),min,31,113261,DB01337,Pancuronium
,2861839,steady state volume of distribution,The steady state volume of distribution was 0.23 litre kg-1 and the clearance 11 ml min-1 kg-1.,Disposition of vecuronium bromide in the cat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),[l] / [kg],0.23,113262,DB01337,Pancuronium
,2861839,clearance,The steady state volume of distribution was 0.23 litre kg-1 and the clearance 11 ml min-1 kg-1.,Disposition of vecuronium bromide in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),[ml] / [kg·min],11,113263,DB01337,Pancuronium
,1590573,FiO2,"Anaesthesia was induced with a bolus dose of thiopental 4 mg/kg body wt, fentanyl 7 micrograms/kg and pancuronium 0.1 mg/kg and maintained with a continuous infusion of fentanyl 20 micrograms/min and mechanical ventilation with O2/N2O at an FiO2 of 0.5.",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.,121198,DB01337,Pancuronium
,1590573,Cardiac output,"Cardiac output (HZV) also decreased from 6.17 l/min to 4.76 l/min after induction, but remained unchanged at sternotomy (Table 2).",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],6.17,121199,DB01337,Pancuronium
,1590573,Cardiac output,"Cardiac output (HZV) also decreased from 6.17 l/min to 4.76 l/min after induction, but remained unchanged at sternotomy (Table 2).",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],4.76,121200,DB01337,Pancuronium
,1590573,Hepatic clearance,Hepatic clearance of thiopental as the product of hepatic extraction of thiopental (with a median value of 0.29) and hepatic plasma flow was 0.21 l/min.,[Hepatic elimination of thiopental in heart surgery patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.29,121201,DB01337,Pancuronium
,1590573,hepatic plasma flow,Hepatic clearance of thiopental as the product of hepatic extraction of thiopental (with a median value of 0.29) and hepatic plasma flow was 0.21 l/min.,[Hepatic elimination of thiopental in heart surgery patients]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],0.21,121202,DB01337,Pancuronium
,1590573,hepatic extraction,Thiopental is subject to a relatively low hepatic extraction of 0.29.,[Hepatic elimination of thiopental in heart surgery patients]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.29,121203,DB01337,Pancuronium
,1590573,hepatic clearance,"The hepatic clearance of thiopental found in this study, with an absolute value of 0.21 l/min, is absolutely comparable with the data for total-body clearance reported in the literature.",[Hepatic elimination of thiopental in heart surgery patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],0.21,121204,DB01337,Pancuronium
,1990898,peak plasma concentration,Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min.,Plasma concentrations of midazolam in children following intranasal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990898/),[ng] / [ml],72.2,121885,DB01337,Pancuronium
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB01337,Pancuronium
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB01337,Pancuronium
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB01337,Pancuronium
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB01337,Pancuronium
,8431572,total body clearance (TBC),"In the VASC group, ME total body clearance (TBC) was 6 +/- 2 mL/kg/min (mean +/- SD), which is less than in previous studies.",Comparison of the pharmacokinetics of methohexital during cardiac surgery with cardiopulmonary bypass and vascular surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431572/),[ml] / [kg·min],6,128144,DB01337,Pancuronium
,2859815,plasma clearance,Vecuronium plasma clearance was reduced significantly (P less than 0.01) from 4.26 +/- 1.38 ml X min-1 X kg-1 in the controls to 2.73 +/- 1.19 ml X min-1 X kg-1 in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[ml] / [kg·min],4.26,130536,DB01337,Pancuronium
,2859815,plasma clearance,Vecuronium plasma clearance was reduced significantly (P less than 0.01) from 4.26 +/- 1.38 ml X min-1 X kg-1 in the controls to 2.73 +/- 1.19 ml X min-1 X kg-1 in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[ml] / [kg·min],2.73,130537,DB01337,Pancuronium
,2859815,elimination half-life,The elimination half-life was 58 +/- 19 min in the controls and was prolonged significantly to 84 +/- 23 min (P less than 0.01) in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,58,130538,DB01337,Pancuronium
,2859815,elimination half-life,The elimination half-life was 58 +/- 19 min in the controls and was prolonged significantly to 84 +/- 23 min (P less than 0.01) in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,84,130539,DB01337,Pancuronium
,2859815,total apparent volume of distribution,The total apparent volume of distribution was unchanged in patients with cirrhosis (0.253 +/- 0.086 1 X kg-1 vs. 0.246 +/- 0.092 1 X kg-1 in the controls).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[1] / [kg],0.253,130540,DB01337,Pancuronium
,2859815,total apparent volume of distribution,The total apparent volume of distribution was unchanged in patients with cirrhosis (0.253 +/- 0.086 1 X kg-1 vs. 0.246 +/- 0.092 1 X kg-1 in the controls).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[1] / [kg],0.246,130541,DB01337,Pancuronium
,2859815,duration of effect,Cirrhosis caused a prolongation of the neuromuscular blockade induced by vecuronium: the duration of effect from injection to 50% recovery of the twitch height was prolonged by 100% (P less than 0.01) from 62 +/- 16 min in the controls to 130 +/- 52 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,62,130542,DB01337,Pancuronium
,2859815,duration of effect,Cirrhosis caused a prolongation of the neuromuscular blockade induced by vecuronium: the duration of effect from injection to 50% recovery of the twitch height was prolonged by 100% (P less than 0.01) from 62 +/- 16 min in the controls to 130 +/- 52 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,130,130543,DB01337,Pancuronium
,2859815,recovery rate (TH 25-75),The recovery rate (TH 25-75) also was prolonged (P less than 0.05) from 21 +/- 7 min in the controls to 44 +/- 18 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,21,130544,DB01337,Pancuronium
,2859815,recovery rate (TH 25-75),The recovery rate (TH 25-75) also was prolonged (P less than 0.05) from 21 +/- 7 min in the controls to 44 +/- 18 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,44,130545,DB01337,Pancuronium
,2719307,time to recover to 50% of maximal twitch depression,"The time course of effect was also similar, although the maximum twitch depression was significantly smaller (66.1% vs. 100% maximal twitch depression) and time to recover to 50% of maximal twitch depression was significantly shorter (14.2 vs. 52 min) in thermally injured patients.",Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719307/),min,14.2,131508,DB01337,Pancuronium
,2719307,time to recover to 50% of maximal twitch depression,"The time course of effect was also similar, although the maximum twitch depression was significantly smaller (66.1% vs. 100% maximal twitch depression) and time to recover to 50% of maximal twitch depression was significantly shorter (14.2 vs. 52 min) in thermally injured patients.",Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719307/),min,52,131509,DB01337,Pancuronium
,1755554,apparent plateau phase (steady state),Those measured during the apparent plateau phase (steady state) of infusion protocol B were close to predicted values (0.5 to 0.6 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),μg,0.5 to 0.6,138071,DB01337,Pancuronium
,1755554,time interval to spontaneous recovery,For all the patients the time interval to spontaneous recovery was 41 +/- 27 min; plasma levels were then 0.199 +/- 0.092 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),min,41,138072,DB01337,Pancuronium
,1755554,plasma levels,For all the patients the time interval to spontaneous recovery was 41 +/- 27 min; plasma levels were then 0.199 +/- 0.092 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),μ,0.199,138073,DB01337,Pancuronium
,6115592,plasma half-lives,"The plasma half-lives varied from 3 to 15 min, and are about one third of that of the structurally-related compound pancuronium.",Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115592/),min,3 to 15,139297,DB01337,Pancuronium
,6115592,Renal excretion,Renal excretion was of the order 5-20% and the biliary excretion 7-20% 6 h after administration of each of the 4 compounds.,Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115592/),%,5-20,139298,DB01337,Pancuronium
,6115592,biliary excretion,Renal excretion was of the order 5-20% and the biliary excretion 7-20% 6 h after administration of each of the 4 compounds.,Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115592/),%,7-20,139299,DB01337,Pancuronium
,588390,terminal half-life,"When compared with the averaged model-independent pharmacokinetic parameters obtained for normal patients, the terminal half-life of 270 min was more than twice normal (132 min, P less than 0.001); the plasma clearance of 59 ml min-1 was less than half the normal rate for pancuronium (123 ml min-1, P less than 0.003).",Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/588390/),min,270,144730,DB01337,Pancuronium
,588390,terminal half-life,"When compared with the averaged model-independent pharmacokinetic parameters obtained for normal patients, the terminal half-life of 270 min was more than twice normal (132 min, P less than 0.001); the plasma clearance of 59 ml min-1 was less than half the normal rate for pancuronium (123 ml min-1, P less than 0.003).",Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/588390/),min,132,144731,DB01337,Pancuronium
,588390,plasma clearance,"When compared with the averaged model-independent pharmacokinetic parameters obtained for normal patients, the terminal half-life of 270 min was more than twice normal (132 min, P less than 0.001); the plasma clearance of 59 ml min-1 was less than half the normal rate for pancuronium (123 ml min-1, P less than 0.003).",Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/588390/),[ml] / [min],59,144732,DB01337,Pancuronium
,588390,plasma clearance,"When compared with the averaged model-independent pharmacokinetic parameters obtained for normal patients, the terminal half-life of 270 min was more than twice normal (132 min, P less than 0.001); the plasma clearance of 59 ml min-1 was less than half the normal rate for pancuronium (123 ml min-1, P less than 0.003).",Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/588390/),[ml] / [min],123,144733,DB01337,Pancuronium
,588390,mean time,"Following a bolus injection of pancuronium 6 mg, there was a mean time of 114 min (normals 70 min, P less than 0.05) before the evoked twitch response had returned to 5% of the control value.",Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/588390/),min,114,144734,DB01337,Pancuronium
,17171862,plasma concentrations,"The doses administered gave plasma concentrations of 1.55 microg/mL, which are considered therapeutic.",Compartmental analysis of lidocaine kinetics during extracorporeal circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171862/),,1.55,147178,DB01337,Pancuronium
,1976829,T1/2 alpha,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,3.9,158846,DB01337,Pancuronium
,1976829,T1/2 beta,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,102,158847,DB01337,Pancuronium
,1976829,V1,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],95,158848,DB01337,Pancuronium
,1976829,Vdss,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],264,158849,DB01337,Pancuronium
,1976829,Cl,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.8,158850,DB01337,Pancuronium
,1976829,V1,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],38,158851,DB01337,Pancuronium
,1976829,Vdss,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],120,158852,DB01337,Pancuronium
,1976829,Cl,"Reflecting the larger central volume of pipecuronium, pipecuronium tended to have a larger clearance than that of pancuroniumu (Cl; 1.1 +/- 0.2 ml.min-1.kg-1).","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.1,158853,DB01337,Pancuronium
,7225266,plasma clearance,"The plasma clearance of pancuronium in patients with extrahepatic cholestasis was 16% lower than in a control group (1.47 +/- 0.11 ml min-1 kg-1 v. 1.76 +/- 0.21 ml min-1 kg-1), but the difference was not significant.",Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),[ml] / [kg·min],1.47,159130,DB01337,Pancuronium
,7225266,plasma clearance,"The plasma clearance of pancuronium in patients with extrahepatic cholestasis was 16% lower than in a control group (1.47 +/- 0.11 ml min-1 kg-1 v. 1.76 +/- 0.21 ml min-1 kg-1), but the difference was not significant.",Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),[ml] / [kg·min],1.76,159131,DB01337,Pancuronium
,7225266,elimination half-life T 1/2 beta,A significant increase in the elimination half-life T 1/2 beta of pancuronium (from 141 to 224 min) and a significant increase in the volume of the peripheral compartment (V2) was found in patients with extrahepatic cholestasis when compared with control patients.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),min,141,159132,DB01337,Pancuronium
,7225266,elimination half-life T 1/2 beta,A significant increase in the elimination half-life T 1/2 beta of pancuronium (from 141 to 224 min) and a significant increase in the volume of the peripheral compartment (V2) was found in patients with extrahepatic cholestasis when compared with control patients.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),min,224,159133,DB01337,Pancuronium
,7225266,cumulative biliary excretion,There was a significantly lower cumulative biliary excretion of pancuronium (0.3 +/- 0.3% v. 10.9 +/- 3.2% in the controls) during the 48-h period of observation.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),%,0.3,159134,DB01337,Pancuronium
,7225266,cumulative biliary excretion,There was a significantly lower cumulative biliary excretion of pancuronium (0.3 +/- 0.3% v. 10.9 +/- 3.2% in the controls) during the 48-h period of observation.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),%,10.9,159135,DB01337,Pancuronium
,7225266,cumulative urinary excretion,The cumulative urinary excretion of gallamine during 48 h in both groups of patients was approximately 100%.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),%,100,159136,DB01337,Pancuronium
,718783,distribution half-life (T 1/2 alpha),A two-fold increase in both the distribution half-life (T 1/2 alpha) from 11 min to 24 min and in the elimination half-life (T 1/2 beta) from 114 min to 208 min was observed in patients with cirrhosis.,Pancuronium pharmacokinetics in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/718783/),min,11,170181,DB01337,Pancuronium
,718783,distribution half-life (T 1/2 alpha),A two-fold increase in both the distribution half-life (T 1/2 alpha) from 11 min to 24 min and in the elimination half-life (T 1/2 beta) from 114 min to 208 min was observed in patients with cirrhosis.,Pancuronium pharmacokinetics in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/718783/),min,24,170182,DB01337,Pancuronium
,718783,elimination half-life (T 1/2 beta),A two-fold increase in both the distribution half-life (T 1/2 alpha) from 11 min to 24 min and in the elimination half-life (T 1/2 beta) from 114 min to 208 min was observed in patients with cirrhosis.,Pancuronium pharmacokinetics in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/718783/),min,114,170183,DB01337,Pancuronium
,718783,elimination half-life (T 1/2 beta),A two-fold increase in both the distribution half-life (T 1/2 alpha) from 11 min to 24 min and in the elimination half-life (T 1/2 beta) from 114 min to 208 min was observed in patients with cirrhosis.,Pancuronium pharmacokinetics in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/718783/),min,208,170184,DB01337,Pancuronium
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,6,171264,DB01337,Pancuronium
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,2,171265,DB01337,Pancuronium
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.15,171266,DB01337,Pancuronium
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.7,171267,DB01337,Pancuronium
,11038831,fractional end tidal alveolar concentration (Fa),The fractional end tidal alveolar concentration (Fa) was adjusted to 1MAC during the maintenance of anesthsia.,"[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),,1,171268,DB01337,Pancuronium
,7023284,plasma clearance,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[ml] / [kg·min],0.38,172247,DB01337,Pancuronium
,7023284,plasma clearance,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[ml] / [kg·min],1.2,172248,DB01337,Pancuronium
,7023284,elimination half-life,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),h,11.4,172249,DB01337,Pancuronium
,7023284,elimination half-life,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),h,6.0,172250,DB01337,Pancuronium
,7023284,total volume of distribution,"The higher serum concentration of metocurine in patients for renal transplant was accounted for by the absence of renal excretion and a reduced total volume of distribution (0.353 vs. 0.472 l/kg, P less than 0.05).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[l] / [kg],0.353,172251,DB01337,Pancuronium
,7023284,total volume of distribution,"The higher serum concentration of metocurine in patients for renal transplant was accounted for by the absence of renal excretion and a reduced total volume of distribution (0.353 vs. 0.472 l/kg, P less than 0.05).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[l] / [kg],0.472,172252,DB01337,Pancuronium
,12631050,CBF,"In group 1, baseline CBF was 55 +/- 7 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],55,176357,DB01337,Pancuronium
,12631050,CBF,Indomethacin decreased CBF to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176358,DB01337,Pancuronium
,12631050,CBF,"In group 2, baseline CBF was 54 +/- 10 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],54,176359,DB01337,Pancuronium
,12631050,CBF,Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176360,DB01337,Pancuronium
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],3.9,176361,DB01337,Pancuronium
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],1.4,176362,DB01337,Pancuronium
,6145374,clearance,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],6.4,178725,DB01337,Pancuronium
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,36,178726,DB01337,Pancuronium
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],3.0,178727,DB01337,Pancuronium
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,72,178728,DB01337,Pancuronium
,3240914,half-lives,"Plasma concentrations decreased biexponentially with half-lives of 9.0 +/- 5.7 min and 140 +/- 36 min, respectively.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),min,9.0,186419,DB01337,Pancuronium
,3240914,half-lives,"Plasma concentrations decreased biexponentially with half-lives of 9.0 +/- 5.7 min and 140 +/- 36 min, respectively.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),min,140,186420,DB01337,Pancuronium
,3240914,volume of the central compartment,"The volume of the central compartment was 0.85 +/- 0.27 L/kg, and the volume of distribution in the steady state was 3.1 +/- 1.1 L/kg.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),[l] / [kg],0.85,186421,DB01337,Pancuronium
,3240914,volume of distribution in the steady state,"The volume of the central compartment was 0.85 +/- 0.27 L/kg, and the volume of distribution in the steady state was 3.1 +/- 1.1 L/kg.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),[l] / [kg],3.1,186422,DB01337,Pancuronium
,3240914,Total plasma clearance,Total plasma clearance was 18 +/- 5 ml/kg/min.,"Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),[ml] / [kg·min],18,186423,DB01337,Pancuronium
,2155718,t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,7.6,199052,DB01337,Pancuronium
,2155718,terminal phase (t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,161,199053,DB01337,Pancuronium
,2155718,central compartment volume,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg],102,199054,DB01337,Pancuronium
,2155718,plasma clearance,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg·min],1.8,199055,DB01337,Pancuronium
,6108730,plasma clearances,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[ml] / [min],221,212973,DB01337,Pancuronium
,6108730,plasma clearances,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[ml] / [min],185,212974,DB01337,Pancuronium
,6108730,terminal half-lives,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),min,30,212975,DB01337,Pancuronium
,6108730,terminal half-lives,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),min,50,212976,DB01337,Pancuronium
,6108730,Mean,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],1.42,212977,DB01337,Pancuronium
,6108730,plasma concentrations at 10,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],1.42,212978,DB01337,Pancuronium
,6108730,plasma concentrations at 10,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],0.88,212979,DB01337,Pancuronium
,6108730,50% recovery,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],1.42,212980,DB01337,Pancuronium
,6108730,50% recovery,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],0.88,212981,DB01337,Pancuronium
,2979128,maximum inspired concentration,"After intubation, anesthesia was maintained with nitrous oxide-oxygen and halothane to a maximum inspired concentration of 0.6%.",Alfentanil in infants and children with congenital heart defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),%,0.6,216495,DB01337,Pancuronium
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],8.2,216496,DB01337,Pancuronium
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],6.3,216497,DB01337,Pancuronium
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,17.6,224536,DB01337,Pancuronium
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,14.7,224537,DB01337,Pancuronium
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB01337,Pancuronium
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB01337,Pancuronium
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB01337,Pancuronium
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB01337,Pancuronium
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB01337,Pancuronium
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB01337,Pancuronium
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB01337,Pancuronium
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB01337,Pancuronium
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB01337,Pancuronium
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB01337,Pancuronium
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB01337,Pancuronium
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB01337,Pancuronium
,2875680,5-25% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,6.0,242933,DB01337,Pancuronium
,2875680,5-25% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,8.8,242934,DB01337,Pancuronium
,2875680,25-75% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,8.7,242935,DB01337,Pancuronium
,2875680,25-75% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,12.6,242936,DB01337,Pancuronium
,6723764,total systemic plasma clearance,"The pharmacokinetic parameters derived for pancuronium were in the range of previously reported values, except that the mean total systemic plasma clearance (0.79 +/- 0.28 ml X min-1 X kg-1) was reduced and the mean terminal phase half-life (169 min) was longer in these patients.",Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[ml] / [kg·min],0.79,268050,DB01337,Pancuronium
,6723764,terminal phase half-life,"The pharmacokinetic parameters derived for pancuronium were in the range of previously reported values, except that the mean total systemic plasma clearance (0.79 +/- 0.28 ml X min-1 X kg-1) was reduced and the mean terminal phase half-life (169 min) was longer in these patients.",Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),min,169,268051,DB01337,Pancuronium
,6723764,'steady-state' Cp necessary,The 'steady-state' Cp necessary to produce 50% paralysis ( ECpss (50] was estimated to be 0.21 +/- 0.08 micrograms X ml-1 (mechanical response) and 0.18 +/- 0.05 micrograms X ml-1 (EMG response).,Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.21,268052,DB01337,Pancuronium
,6723764,'steady-state' Cp necessary,The 'steady-state' Cp necessary to produce 50% paralysis ( ECpss (50] was estimated to be 0.21 +/- 0.08 micrograms X ml-1 (mechanical response) and 0.18 +/- 0.05 micrograms X ml-1 (EMG response).,Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.18,268053,DB01337,Pancuronium
,6723764,effective plasma concentrations for 50% paralysis ( ECp50 ),"An analysis using the Hill equation of the Cp-response relationship, during and after the constant-rate infusion of pancuronium bromide, resulted in effective plasma concentrations for 50% paralysis ( ECp50 ) of 0.35 +/- 0.06 micrograms X ml-1 and 0.20 +/- 0.09 micrograms X ml-1, respectively, for mechanical twitch response.",Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.35,268054,DB01337,Pancuronium
,6723764,effective plasma concentrations for 50% paralysis ( ECp50 ),"An analysis using the Hill equation of the Cp-response relationship, during and after the constant-rate infusion of pancuronium bromide, resulted in effective plasma concentrations for 50% paralysis ( ECp50 ) of 0.35 +/- 0.06 micrograms X ml-1 and 0.20 +/- 0.09 micrograms X ml-1, respectively, for mechanical twitch response.",Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.20,268055,DB01337,Pancuronium
,6723764,EMG,The corresponding values for EMG response were 0.32 +/- 0.06 micrograms X ml-1 and 0.17 +/- 0.06 micrograms X ml-1.,Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.32,268056,DB01337,Pancuronium
,6723764,EMG,The corresponding values for EMG response were 0.32 +/- 0.06 micrograms X ml-1 and 0.17 +/- 0.06 micrograms X ml-1.,Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.17,268057,DB01337,Pancuronium
,6723764,response,The corresponding values for EMG response were 0.32 +/- 0.06 micrograms X ml-1 and 0.17 +/- 0.06 micrograms X ml-1.,Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.32,268058,DB01337,Pancuronium
,6723764,response,The corresponding values for EMG response were 0.32 +/- 0.06 micrograms X ml-1 and 0.17 +/- 0.06 micrograms X ml-1.,Pharmacokinetic and pharmacodynamic modelling with pancuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723764/),[μg] / [ml],0.17,268059,DB01337,Pancuronium
